Regarding heart failure and issues leading up to that:
The big issue for drug developers is that the FDA will require an outcomes trial, and we all know or think we know what that means in terms of efficacy needed and the time and expense of such a trial or trials. With companies getting out of the cardiology arena, there will be limited players in this field.
Here is an interesting company and approach in the cardiolgy and microRNA field, in which Eric Olson is a founder. He was a founder of Myogen, a company previously bought out at a really high price by GILD. (Can anyone recall the products that GILD sells from the Myogen buyout?)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.